---
title: "Gibraltar and Europe"
image: "https:\/\/i.ytimg.com\/vi\/z1eQw7x6D1E\/hqdefault.jpg"
vid_id: "z1eQw7x6D1E"
categories: "Education"
tags: ["physiology","nursing","NCLEX"]
date: "2021-11-25T05:17:00+03:00"
vid_date: "2021-11-24T22:27:56Z"
duration: "PT24M51S"
viewcount: "69717"
likeCount: "3284"
dislikeCount: "155"
channel: "Dr. John Campbell"
---
{% raw %}Gibraltar<br /><br />Population, 33,691<br /><br />Has administered at least 94,469 vaccine doses<br /><br />Enough to have fully vaccinated 140.2% of the country’s population. <br /><br />Face masks required in all shops and supermarkets, public transport, in medical centres, indoor funerals, Airport.<br /><br /><a rel="nofollow" target="blank" href="https://www.worldometers.info/coronavirus/country/gibraltar/">https://www.worldometers.info/coronavirus/country/gibraltar/</a><br /><br />Europe<br /><br /><a rel="nofollow" target="blank" href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019">https://www.who.int/emergencies/diseases/novel-coronavirus-2019</a><br /><br />World Health Organization<br /><br />Europe remains “in the firm grip”<br /><br />Death toll could top 2.2 million this winter<br /><br />Another 700,000 deaths by March 1<br /><br />high or extreme stress in intensive care units (ICUs) in 49 out of 53 countries between now and March 1, 2022<br /><br />Director for WHO Europe, Hans Kluge<br /><br />face a challenging winter ahead<br /><br />vaccine plus<br /><br />Face masks reduce COVID incidence <br />by 53 %<br /><br />Over 160,000 deaths could be prevented (by March 1) if universal mask coverage of 95%<br /><br /><br />Pascal Soriot, the chief executive of AstraZeneca<br /><br /><a rel="nofollow" target="blank" href="https://www.telegraph.co.uk/news/2021/11/23/astrazeneca-jab-could-reason-britain-faring-better-europe-says/">https://www.telegraph.co.uk/news/2021/11/23/astrazeneca-jab-could-reason-britain-faring-better-europe-says/</a><br /><br />UK not seeing so many hospitalisations relative to Europe despite a high number of cases.<br /><br />Long term T cell immunity after antibodies wane<br /><br />Looks like, AstraZeneca initially gives higher levels of T-cells<br /><br />France, Germany, Spain, Belgium – restricted AZ to the under 65s<br /><br />UK may have high T cells from natural infection and cross immunity from other coronavirus infections<br /><br />Government source<br /><br />European leaders had all these unfounded concerns about AstraZeneca and its use in older people<br /><br />If you look at the data, you can see us using it early has been incredibly helpful in terms of protecting older and vulnerable people from this disease for longer<br /><br />Dr Peter English<br /><br />People whose immune systems have produced a strong T-cell response but a weaker antibody response might be more likely to be infected in the first place <br /><br />but more likely to be able to fight the infection, and they will be much less likely to develop severe disease<br /><br />It is plausible that this generated an excellent T-cell response, which means that while people can still be infected and infectious, they are unlikely to be seriously unwell<br /><br />Prof Matthew Snape, Oxford University<br /><br />The best T-cell responses seem to come if you give a first dose of the AstraZeneca vaccine followed by Pfizer<br /><br />Prof Dame Sarah Gilbert<br /><br />Third jabs may be unnecessary<br /><br />UK<br /><br /><a rel="nofollow" target="blank" href="https://coronavirus.data.gov.uk">https://coronavirus.data.gov.uk</a><br /><br />US<br /><br /><a rel="nofollow" target="blank" href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html">https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html</a><br /><br />Centers for Disease Control and Prevention Director Rochelle Walensky<br /><br />Seven-day average<br /><br />Cases up 18%<br /><br />Hospital admissions up 6%<br /><br />135 million people eligible for boosters<br /><br />Heading into the winter months, when respiratory viruses are more likely to spread,<br /> <br />and with plans for increased holiday season travel and gatherings, <br /><br />boosting people’s overall protection against covid-19 disease and death was important to do now<br /><br />In the fully vaccinated<br /><br /><a rel="nofollow" target="blank" href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html</a><br /><br />Infections happen in only a small proportion of people who are fully vaccinated, even with the Delta variant. <br /><br />When these infections occur among vaccinated people, they tend to be mild<br /><br />If you are fully vaccinated and become infected with the Delta variant, you can spread the virus to others<br /><br />Dr Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases<br /><br /><a rel="nofollow" target="blank" href="https://www.businessinsider.com/fauci-babies-toddlers-should-get-covid-19-vaccines-by-spring-2021-11">https://www.businessinsider.com/fauci-babies-toddlers-should-get-covid-19-vaccines-by-spring-2021-11</a><br /><br />Next spring<br /><br />Pfizer trial ongoing<br /><br />6 months to 5 years<br /><br />Moderna and Johnson &amp; Johnson, have pediatric vaccine trials planned<br /><br />Emergency use authorization to the Food and Drug Administration<br /><br />Canada<br /><br /><a rel="nofollow" target="blank" href="https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html">https://www.canada.ca/en/health-canada/news/2021/11/health-canada-authorizes-use-of-comirnaty-the-pfizer-biontech-covid-19-vaccine-in-children-5-to-11-years-of-age.html</a><br /><br />Health Canada<br /><br />Pfizer-BioNTech Comirnaty, in children 5 to 11 years<br /><br />(12 to 15s, May 5, 2021)<br /><br />the Department has determined that the benefits of this vaccine for children between 5 and 11 years of age outweigh the risks<br /><br />Two-dose regimen, 10 micrograms<br /><br />Three weeks apart<br /><br />Immune response in children 5 to 11 years, comparable to 16 to 25<br /><br />The vaccine was 90.7% effective at preventing COVID-19 in children 5 to 11 years of age<br /><br />and no serious side effects were identified<br /><br />Ongoing studies and real-world data<br /><br />to ensure that the benefits of the vaccine continue to outweigh any risks, as well as to detect any potential new safety signals in any age group{% endraw %}
